Elicera Therapeutics (ELIC.ST)

Executive Summary

Elicera Therapeutics is a clinical-stage Swedish immuno-oncology company developing next-generation CAR T-cell and oncolytic virus therapies enhanced by its proprietary iTANK (immunomodulatory T-cell activating nanoparticle) platform. The iTANK technology is designed to boost the persistence and efficacy of engineered T-cells and oncolytic viruses, particularly against solid tumors, which pose significant challenges for conventional cell therapies. The company’s lead program, ELC-301, is a CAR T-cell therapy targeting CD20 with iTANK co-stimulation, currently in a Phase 1/2 trial for relapsed/refractory B-cell malignancies. Additionally, Elicera is advancing oncolytic virus candidates that leverage iTANK to remodel the tumor microenvironment and induce systemic anti-tumor immunity. The company’s differentiated approach addresses key limitations of current CAR T-cell therapies, such as limited persistence and immune suppression in solid tumors. Elicera has reported encouraging early safety and efficacy data from its Phase 1/2 trial, with expansion cohorts underway. With a market capitalization around $162 million and a lean operational model, the company represents a high-risk, high-reward opportunity in the cell and gene therapy space. Upcoming milestones include initial data from the ongoing study and potential advancement of its oncolytic virus program into the clinic. Success in demonstrating durable responses could validate the iTANK platform and unlock significant value.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data for lead CAR T candidate (ELC-301)70% success
• Q4 2026Initiation of Phase 1/2 trial for oncolytic virus candidate (ELC-401)60% success
• H1 2027Potential technology partnership or licensing deal for iTANK platform50% success